CAS: 22282-99-1; 4-Bromo-2-Methylpyridine

相似化合物

5093-70-9 79055-52-0 1196155-22-2

上下游产品

3-methyl-4-pyridinamine 2-methyl-4-nitro-pyridine Acetyl bromide chloroform 2-(2-hydroxy-ethyl)-pyridin-4-ol 2-(4-bromopyridin-2-yl)ethanol 4-bromo-2-methylpyridine N-oxide 4-bromo-2-picolinic acid

2-甲基吡啶氧化物置于乙酰溴,硫酸,硝酸,三氯化磷体系中,用 氯仿 用作溶剂,化学反应 11.0H,反应生成4-溴-2-甲基吡啶
参考文献:新型1,4-二氢吡啶类钙拮抗剂.I.4-(取代的吡啶基)-1,4-二氢吡啶衍生物的合成和降血压活性.
标题:新型1,4-二氢吡啶类钙拮抗剂.I.4-(取代的吡啶基)-1,4-二氢吡啶衍生物的合成和降血压活性.
摘要:合成了一系列4-(取代的吡啶基)-1,4-二氢吡啶衍生物,并研究了它们的降压作用.几种化合物,2-(n-苄基-N-甲基氨基)乙基甲基1,4-二氢-2,6-二甲基-4-(3-硝基-2-吡啶基)-3,5-吡啶二甲酸(2B),4-(4-硝基-2-吡啶基)类似物(2G),4-(3-三氟甲基-2-吡啶基)类似物(2C),4-(2-三氟甲基-3-吡啶基)类似物(3E),4-发现(4-氰基-2-吡啶基)类似物(2E),4-(2-氰基-3-吡啶基)类似物(3D)和4-(6-溴-2-吡啶基)类似物(2I)具有与尼卡地平类似的降压活动;特别是2C和3E的持续时间约为尼卡地平的两倍,而2E具有在所有合成衍生物中最有效的降压活性.
Doi:10.1248/cpb.38.2446

专利信息

专利号:WO-2023086801-A1
优先权日:2021-11-09
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-12428425-B2
优先权日:2020-05-04
标 题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：CZABANIUK LARA C; HOPPER TIMOTHY; HOUZE JONATHAN B; PANTELEEV JANE; RESCOURIO GWENAELLA; SANTORA VINCENT; WANG HAOXUAN; WHITE RYAN D; WONG ALICE R; WU YONGWEI; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:AMGEN INC; VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-12150934-B2
优先权日:2016-11-30
标 题 :Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
发明人：SIDDIQUI ARSHAD M; CIBLAT STEPHANE; CONSTANTINEAU-FORGET LEA; GRAND-MAITRE CHANTAL; GUO XIANGYU; SRIVASTAVA SANJAY; SHIPPS GERALD W; COOPER ALAN B; OZA VIBHA; KOSTURA MATTHEW W; LUTHER MICHAEL; LEVINE JEDD
权利人:BANTAM PHARMACEUTICAL LLC
摘要:Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by “aâ€?, R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

专利号:WO-2015088565-A1
优先权日:2013-12-13
标题:P2x4 receptor modulating compounds and methods of use thereof
发明人：NEWCOM JASON S; SPEAR KERRY L
权利人:SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are P2X4 receptor modulating compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including but not limited to, chronic pain, neuropathy, inflammatory diseases and central nervous system disorders.

专利号:US-5958954-A
优先权日:1995-09-01
标题 :Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.